Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UCB’s Keppra XR Wins FDA Approval

This article was originally published in The Pink Sheet Daily

Executive Summary

Extended-release tabs set to beat Keppra generics to pharmacy shelves.

You may also be interested in...



Older Primary Care Drugs Matter – For Cash, And For Emerging Market Access

Europe's mid-sized pharma may be going specialist like much of the rest of the industry, including some of the biggest companies

Prevacid, Topamax Among Blockbusters Set To Lose Exclusivity In ’09

At least four blockbuster drugs could face generic rivals in the U.S. for the first time in 2009

Prevacid, Topamax Among Blockbusters Set To Lose Exclusivity In ’09

At least four blockbuster drugs could face generic rivals in the U.S. for the first time in 2009

Related Content

Topics

UsernamePublicRestriction

Register

ID1122310

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel